Certara Inc (CERT)

Certara Inc. recorded one insider transaction over the past ninety days, involving a proposed sale of 36,066 shares valued at approximately $300,069 by officer Leif E. Pedersen. This activity follows a recent earnings report where the company missed expectations. The stock has experienced significant volatility, currently trading well below its annual peak.
Ticker: CERT Exchange: NSM


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Certara Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Pedersen Leif E Officer Officer
Transaction date
Proposed sale
Price
464.75
Quantity 26,104
Value US$2,028,832
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Purchase
Price
322.69
Quantity 2,596 +11.7%
Value US$4,266,854
Pedersen Leif E PRESIDENT, CHIEF COMMERCAL OFF Officer
Transaction date
Planned sale
Price
144.74
Quantity 60,829 -2.3%
Value US$4,099,613
Pedersen Leif E Officer Officer
Transaction date
Proposed sale
Price
10.92
Quantity 51,224
Value US$559,304
SMITH PATRICK F Officer Officer
Transaction date
Proposed sale
Price
9.73
Quantity 20,142
Value US$195,982
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
11.03
Quantity 5,409 -9.7%
Value US$59,661
SMITH PATRICK F Officer Officer
Transaction date
Proposed sale
Price
11.03
Quantity 5,409
Value US$59,661
Pedersen Leif E PRESIDENT, CHIEF COMMERCAL OFF Officer
Transaction date
Planned sale
Price
11.29
Quantity 51,224 -33.9%
Value US$578,319
Pedersen Leif E Officer Officer
Transaction date
Proposed sale
Price
11.29
Quantity 51,224
Value US$578,450
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
17.77
Quantity 422 -0.8%
Value US$7,499
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
16.77
Quantity 4,740 -8.6%
Value US$79,490
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
17.67
Quantity 328 -0.6%
Value US$5,796
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
16.75
Quantity 3,024 -5.2%
Value US$50,652
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
17.72
Quantity 649 -1.1%
Value US$11,500
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
16.76
Quantity 5,264 -8.2%
Value US$88,225
SMITH PATRICK F Officer Officer
Transaction date
Proposed sale
Price
17.62
Quantity 14,427
Value US$254,204
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
18.00
Quantity 3,000 -1.7%
Value US$54,000
Traynor Richard M. Officer Officer
Transaction date
Proposed sale
Price
18.00
Quantity 3,000
Value US$54,000
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
18.28
Quantity 3,000 -1.8%
Value US$54,840
Traynor Richard M. Officer Officer
Transaction date
Proposed sale
Price
18.28
Quantity 3,000
Value US$54,840
SMITH PATRICK F PRESIDENT, DRUG DEV SOLUTIONS Officer
Transaction date
Planned sale
Price
18.00
Quantity 5,000 -8.3%
Value US$90,000
SMITH PATRICK F Officer Officer
Transaction date
Proposed sale
Price
18.00
Quantity 5,000
Value US$90,000
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
18.00
Quantity 6,000 -3.5%
Value US$108,000
Traynor Richard M. Officer Officer
Transaction date
Proposed sale
Price
18.00
Quantity 6,000
Value US$108,000
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
18.00
Quantity 6,000 -3.4%
Value US$108,000
Traynor Richard M. Officer Officer
Transaction date
Proposed sale
Price
18.00
Quantity 6,000
Value US$108,000
Pedersen Leif E PRESIDENT, CHIEF COMMERCAL OFF Officer
Transaction date
Planned sale
Price
14.60
Quantity 51,224 -28.4%
Value US$747,870
Pedersen Leif E Officer Officer
Transaction date
Proposed sale
Price
14.60
Quantity 51,224
Value US$748,065
1.7
BROSHY ERAN Non-Executive Director
Transaction date
Purchase
Price
15.80
Quantity 4,807 +50.3%
Value US$75,951
1.7
BROSHY ERAN Non-Executive Director
Transaction date
Purchase
Price
16.10
Quantity 193 +2.1%
Value US$3,107
SMITH PATRICK F PRESIDENT, INTEGRATED DRUG DEV Officer
Transaction date
Planned sale
Price
21.55
Quantity 19,104 -24.2%
Value US$411,691
SMITH PATRICK F Officer Officer
Transaction date
Proposed sale
Price
21.55
Quantity 19,104
Value US$411,691
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
20.82
Quantity 5,000 -2.7%
Value US$104,100
Traynor Richard M. Officer Officer
Transaction date
Proposed sale
Price
20.82
Quantity 5,000
Value US$104,100
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
23.66
Quantity 5,000 -2.7%
Value US$118,300
Traynor Richard M. Officer Officer
Transaction date
Proposed sale
Price
23.66
Quantity 5,000
Value US$118,300
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
21.45
Quantity 10,000 -5.1%
Value US$214,500
Traynor Richard M. Officer Officer
Transaction date
Proposed sale
Price
21.45
Quantity 10,000
Value US$214,500
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
20.00
Quantity 15,000 -7.2%
Value US$300,000
2.6
EQT Avatar Parent L.P. Large shareholder
Transaction date
Sale
Price
15.00
Quantity 29,954,521 -100.0%
Value US$449,317,815
Pedersen Leif E PRESIDENT, SOFTWARE Officer
Transaction date
Planned sale
Price
15.55
Quantity 51,223 -22.6%
Value US$796,518
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
15.57
Quantity 245,793 -27.1%
Value US$3,826,997
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
15.27
Quantity 4,207 -0.5%
Value US$64,241
1.8
WALSH MATTHEW M Non-Executive Director
Transaction date
Sale
Price
14.74
Quantity 12,059 -6.7%
Value US$177,750
SMITH PATRICK F PRESIDENT, INTEGRATED DRUG DEV Officer
Transaction date
Planned sale
Price
13.48
Quantity 2,387 -3.1%
Value US$32,177
0.8
McLean Stephen M. Non-Executive Director
Transaction date
Purchase
Price
16.32
Quantity 20,000 +90.9%
Value US$326,400
0.9
Schemick Michael Andrew CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
16.64
Quantity 25,000 +5.1%
Value US$416,000
SMITH PATRICK F PRESIDENT, INTEGRATED DRUG DEV Officer
Transaction date
Planned sale
Price
17.71
Quantity 10,000 -11.3%
Value US$177,100
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
17.38
Quantity 182,475 -16.7%
Value US$3,171,416
2.6
EQT Avatar Parent L.P. Large shareholder
Transaction date
Sale
Price
17.38
Quantity 6,004,418 -16.7%
Value US$104,356,785
SMITH PATRICK F PRESIDENT, INTEGRATED DRUG DEV Officer
Transaction date
Planned sale
Price
19.16
Quantity 10,000 -10.2%
Value US$191,600
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
19.52
Quantity 50,000 -4.4%
Value US$976,000
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
19.59
Quantity 100,000 -8.0%
Value US$1,959,000
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
19.55
Quantity 100,000 -7.4%
Value US$1,955,000
2.6
EQT Avatar Parent L.P. Large shareholder
Transaction date
Sale
Price
19.00
Quantity 1,500,000 -4.0%
Value US$28,500,000
SMITH PATRICK F PRESIDENT, INTEGRATED DRUG DEV Officer
Transaction date
Planned sale
Price
22.29
Quantity 3,352 -3.3%
Value US$74,716
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
20.25
Quantity 125,000 -8.5%
Value US$2,531,250
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Sale
Price
20.17
Quantity 125,000 -7.8%
Value US$2,521,250
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
20.00
Quantity 3,000 -1.4%
Value US$60,000
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
20.17
Quantity 62,485 -2.8%
Value US$1,260,322
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
20.29
Quantity 27,515 -1.2%
Value US$558,279
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
23.93
Quantity 4,706 -0.2%
Value US$112,615
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
23.31
Quantity 70,294 -3.0%
Value US$1,638,553
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
25.49
Quantity 6,518 -0.3%
Value US$166,144
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
24.93
Quantity 30,075 -1.3%
Value US$749,770
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
23.83
Quantity 53,407 -2.2%
Value US$1,272,689
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Planned sale
Price
26.80
Quantity 14,801 -0.9%
Value US$396,667
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Planned sale
Price
26.53
Quantity 35,199 -2.1%
Value US$933,829
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
26.01
Quantity 3,000 -1.4%
Value US$78,030
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
25.67
Quantity 51,196 -2.1%
Value US$1,314,201
1.5
Feehery William F CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Planned sale
Price
24.72
Quantity 23,804 -0.9%
Value US$588,435
Edge Justin PRES., REGULATORY & ACCESS Officer
Transaction date
Planned sale
Price
27.50
Quantity 5,000 -1.2%
Value US$137,500
Traynor Richard M. SVP AND GENERAL COUNSEL Officer
Transaction date
Planned sale
Price
27.44
Quantity 5,000 -2.2%
Value US$137,200
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Planned sale
Price
28.88
Quantity 9,677 -0.6%
Value US$279,472
3.3
SLAINE MASON P Non-Executive Director
Transaction date
Planned sale
Price
28.57
Quantity 40,323 -2.4%
Value US$1,152,028
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-09-03 2026-09-03 PrS Proposed sale

Officer

Officer
26,104
464.75
US$2,028,832
26,104 464.75 US$2,028,832
2025-11-12 2025-11-11 B Purchase

CHIEF EXECUTIVE OFFICER

Executive Director
2,596 +11.7%
322.69
US$4,266,854
2,596 +11.7% 322.69 US$4,266,854
2025-09-11 2025-09-09 PlS Planned sale

PRESIDENT, CHIEF COMMERCAL OFF

Officer
60,829 -2.3%
144.74
US$4,099,613
60,829 -2.3% 144.74 US$4,099,613
2025-09-09 2025-09-09 PrS Proposed sale

Officer

Officer
51,224
10.92
US$559,304
51,224 10.92 US$559,304
2025-04-02 2025-04-02 PrS Proposed sale

Officer

Officer
20,142
9.73
US$195,982
20,142 9.73 US$195,982
2024-10-08 2024-10-07 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
5,409 -9.7%
11.03
US$59,661
5,409 -9.7% 11.03 US$59,661
2024-10-07 2024-10-07 PrS Proposed sale

Officer

Officer
5,409
11.03
US$59,661
5,409 11.03 US$59,661
2024-09-10 2024-09-09 PlS Planned sale

PRESIDENT, CHIEF COMMERCAL OFF

Officer
51,224 -33.9%
11.29
US$578,319
51,224 -33.9% 11.29 US$578,319
2024-09-09 2024-09-09 PrS Proposed sale

Officer

Officer
51,224
11.29
US$578,450
51,224 11.29 US$578,450
2024-04-04 2024-04-02 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
422 -0.8%
17.77
US$7,499
422 -0.8% 17.77 US$7,499
2024-04-04 2024-04-02 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
4,740 -8.6%
16.77
US$79,490
4,740 -8.6% 16.77 US$79,490
2024-04-04 2024-04-02 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
328 -0.6%
17.67
US$5,796
328 -0.6% 17.67 US$5,796
2024-04-04 2024-04-02 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
3,024 -5.2%
16.75
US$50,652
3,024 -5.2% 16.75 US$50,652
2024-04-04 2024-04-02 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
649 -1.1%
17.72
US$11,500
649 -1.1% 17.72 US$11,500
2024-04-04 2024-04-02 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
5,264 -8.2%
16.76
US$88,225
5,264 -8.2% 16.76 US$88,225
2024-04-02 2024-04-02 PrS Proposed sale

Officer

Officer
14,427
17.62
US$254,204
14,427 17.62 US$254,204
2024-04-03 2024-04-01 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
3,000 -1.7%
18.00
US$54,000
3,000 -1.7% 18.00 US$54,000
2024-04-01 2024-04-01 PrS Proposed sale

Officer

Officer
3,000
18.00
US$54,000
3,000 18.00 US$54,000
2024-03-05 2024-03-04 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
3,000 -1.8%
18.28
US$54,840
3,000 -1.8% 18.28 US$54,840
2024-03-04 2024-03-04 PrS Proposed sale

Officer

Officer
3,000
18.28
US$54,840
3,000 18.28 US$54,840
2024-02-21 2024-02-20 PlS Planned sale

PRESIDENT, DRUG DEV SOLUTIONS

Officer
5,000 -8.3%
18.00
US$90,000
5,000 -8.3% 18.00 US$90,000
2024-02-20 2024-02-20 PrS Proposed sale

Officer

Officer
5,000
18.00
US$90,000
5,000 18.00 US$90,000
2024-02-14 2024-02-12 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
6,000 -3.5%
18.00
US$108,000
6,000 -3.5% 18.00 US$108,000
2024-02-12 2024-02-12 PrS Proposed sale

Officer

Officer
6,000
18.00
US$108,000
6,000 18.00 US$108,000
2023-12-27 2023-12-26 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
6,000 -3.4%
18.00
US$108,000
6,000 -3.4% 18.00 US$108,000
2023-12-26 2023-12-26 PrS Proposed sale

Officer

Officer
6,000
18.00
US$108,000
6,000 18.00 US$108,000
2023-09-12 2023-09-11 PlS Planned sale

PRESIDENT, CHIEF COMMERCAL OFF

Officer
51,224 -28.4%
14.60
US$747,870
51,224 -28.4% 14.60 US$747,870
2023-09-11 2023-09-11 PrS Proposed sale

Officer

Officer
51,224
14.60
US$748,065
51,224 14.60 US$748,065
2023-08-23 2023-08-22 B Purchase Non-Executive Director
4,807 +50.3%
15.80
US$75,951
4,807 +50.3% 15.80 US$75,951
2023-08-23 2023-08-21 B Purchase Non-Executive Director
193 +2.1%
16.10
US$3,107
193 +2.1% 16.10 US$3,107
2023-06-06 2023-06-05 PlS Planned sale

PRESIDENT, INTEGRATED DRUG DEV

Officer
19,104 -24.2%
21.55
US$411,691
19,104 -24.2% 21.55 US$411,691
2023-06-05 2023-06-05 PrS Proposed sale

Officer

Officer
19,104
21.55
US$411,691
19,104 21.55 US$411,691
2023-05-15 2023-05-11 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
5,000 -2.7%
20.82
US$104,100
5,000 -2.7% 20.82 US$104,100
2023-05-11 2023-05-11 PrS Proposed sale

Officer

Officer
5,000
20.82
US$104,100
5,000 20.82 US$104,100
2023-04-17 2023-04-14 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
5,000 -2.7%
23.66
US$118,300
5,000 -2.7% 23.66 US$118,300
2023-04-14 2023-04-14 PrS Proposed sale

Officer

Officer
5,000
23.66
US$118,300
5,000 23.66 US$118,300
2023-03-07 2023-03-06 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
10,000 -5.1%
21.45
US$214,500
10,000 -5.1% 21.45 US$214,500
2023-03-06 2023-03-06 PrS Proposed sale

Officer

Officer
10,000
21.45
US$214,500
10,000 21.45 US$214,500
2023-02-03 2023-02-02 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
15,000 -7.2%
20.00
US$300,000
15,000 -7.2% 20.00 US$300,000
2022-12-12 2022-12-08 S Sale Large shareholder
29,954,521 -100.0%
15.00
US$449,317,815
29,954,521 -100.0% 15.00 US$449,317,815
2022-11-23 2022-11-22 PlS Planned sale

PRESIDENT, SOFTWARE

Officer
51,223 -22.6%
15.55
US$796,518
51,223 -22.6% 15.55 US$796,518
2022-11-16 2022-11-15 S Sale Non-Executive Director
245,793 -27.1%
15.57
US$3,826,997
245,793 -27.1% 15.57 US$3,826,997
2022-11-16 2022-11-14 S Sale Non-Executive Director
4,207 -0.5%
15.27
US$64,241
4,207 -0.5% 15.27 US$64,241
2022-11-15 2022-11-14 S Sale Non-Executive Director
12,059 -6.7%
14.74
US$177,750
12,059 -6.7% 14.74 US$177,750
2022-11-14 2022-11-09 PlS Planned sale

PRESIDENT, INTEGRATED DRUG DEV

Officer
2,387 -3.1%
13.48
US$32,177
2,387 -3.1% 13.48 US$32,177
2022-08-23 2022-08-19 B Purchase Non-Executive Director
20,000 +90.9%
16.32
US$326,400
20,000 +90.9% 16.32 US$326,400
2022-08-18 2022-08-17 B Purchase

CHIEF FINANCIAL OFFICER

Officer
25,000 +5.1%
16.64
US$416,000
25,000 +5.1% 16.64 US$416,000
2022-08-18 2022-08-16 PlS Planned sale

PRESIDENT, INTEGRATED DRUG DEV

Officer
10,000 -11.3%
17.71
US$177,100
10,000 -11.3% 17.71 US$177,100
2022-08-17 2022-08-16 S Sale Non-Executive Director
182,475 -16.7%
17.38
US$3,171,416
182,475 -16.7% 17.38 US$3,171,416
2022-08-17 2022-08-16 S Sale Large shareholder
6,004,418 -16.7%
17.38
US$104,356,785
6,004,418 -16.7% 17.38 US$104,356,785
2022-06-09 2022-06-08 PlS Planned sale

PRESIDENT, INTEGRATED DRUG DEV

Officer
10,000 -10.2%
19.16
US$191,600
10,000 -10.2% 19.16 US$191,600
2022-06-03 2022-06-02 S Sale Non-Executive Director
50,000 -4.4%
19.52
US$976,000
50,000 -4.4% 19.52 US$976,000
2022-06-03 2022-06-02 S Sale Non-Executive Director
100,000 -8.0%
19.59
US$1,959,000
100,000 -8.0% 19.59 US$1,959,000
2022-06-03 2022-06-02 S Sale Non-Executive Director
100,000 -7.4%
19.55
US$1,955,000
100,000 -7.4% 19.55 US$1,955,000
2022-06-01 2022-05-31 S Sale Large shareholder
1,500,000 -4.0%
19.00
US$28,500,000
1,500,000 -4.0% 19.00 US$28,500,000
2022-04-05 2022-04-04 PlS Planned sale

PRESIDENT, INTEGRATED DRUG DEV

Officer
3,352 -3.3%
22.29
US$74,716
3,352 -3.3% 22.29 US$74,716
2022-03-18 2022-03-17 S Sale Non-Executive Director
125,000 -8.5%
20.25
US$2,531,250
125,000 -8.5% 20.25 US$2,531,250
2022-03-18 2022-03-16 S Sale Non-Executive Director
125,000 -7.8%
20.17
US$2,521,250
125,000 -7.8% 20.17 US$2,521,250
2022-03-18 2022-03-16 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
3,000 -1.4%
20.00
US$60,000
3,000 -1.4% 20.00 US$60,000
2022-03-17 2022-03-16 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
62,485 -2.8%
20.17
US$1,260,322
62,485 -2.8% 20.17 US$1,260,322
2022-03-14 2022-03-11 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
27,515 -1.2%
20.29
US$558,279
27,515 -1.2% 20.29 US$558,279
2022-02-22 2022-02-18 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
4,706 -0.2%
23.93
US$112,615
4,706 -0.2% 23.93 US$112,615
2022-02-22 2022-02-18 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
70,294 -3.0%
23.31
US$1,638,553
70,294 -3.0% 23.31 US$1,638,553
2022-02-22 2022-02-17 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
6,518 -0.3%
25.49
US$166,144
6,518 -0.3% 25.49 US$166,144
2022-02-22 2022-02-17 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
30,075 -1.3%
24.93
US$749,770
30,075 -1.3% 24.93 US$749,770
2022-02-22 2022-02-17 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
53,407 -2.2%
23.83
US$1,272,689
53,407 -2.2% 23.83 US$1,272,689
2022-02-02 2022-02-01 PlS Planned sale Non-Executive Director
14,801 -0.9%
26.80
US$396,667
14,801 -0.9% 26.80 US$396,667
2022-02-02 2022-02-01 PlS Planned sale Non-Executive Director
35,199 -2.1%
26.53
US$933,829
35,199 -2.1% 26.53 US$933,829
2022-01-27 2022-01-26 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
3,000 -1.4%
26.01
US$78,030
3,000 -1.4% 26.01 US$78,030
2022-01-27 2022-01-26 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
51,196 -2.1%
25.67
US$1,314,201
51,196 -2.1% 25.67 US$1,314,201
2022-01-27 2022-01-26 PlS Planned sale

CHIEF EXECUTIVE OFFICER

Executive Director
23,804 -0.9%
24.72
US$588,435
23,804 -0.9% 24.72 US$588,435
2022-01-21 2022-01-20 PlS Planned sale

PRES., REGULATORY & ACCESS

Officer
5,000 -1.2%
27.50
US$137,500
5,000 -1.2% 27.50 US$137,500
2022-01-20 2022-01-18 PlS Planned sale

SVP AND GENERAL COUNSEL

Officer
5,000 -2.2%
27.44
US$137,200
5,000 -2.2% 27.44 US$137,200
2022-01-04 2022-01-03 PlS Planned sale Non-Executive Director
9,677 -0.6%
28.88
US$279,472
9,677 -0.6% 28.88 US$279,472
2022-01-04 2022-01-03 PlS Planned sale Non-Executive Director
40,323 -2.4%
28.57
US$1,152,028
40,323 -2.4% 28.57 US$1,152,028